Non-small cell lung cancer
Conditions
Interventions
Traditional Chinese Medicine intervention group:The patient will initially take a fixed traditional Chinese medicine (TCM) prescription, which is formulated by integrating AI large model technology wi
Sponsors
Dongfang Hospital,Beijing University of Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1) NSCLC patients diagnosed by cytology or histology; classified as stage IIIb to IV according to the 9th edition of the TNM staging system for lung cancer published by the International Association for the Study of Lung Cancer (IASLC); 2) Patients meeting the TCM diagnostic criteria and diagnosed with any one of the five syndrome types of lung cancer according to the syndrome differentiation scheme of the "Traditional Chinese Medicine Diagnosis and Treatment Protocol for Lung Cancer (2017)" issued by the State Administration of Traditional Chinese Medicine; 3) Age > 18 years; 4) Performance status score (Eastern Cooperative Oncology Group, ECOG) of 2-3 and expected survival > 3 months; 5) Patients who have experienced disease progression, are unable to tolerate, or are medically unsuitable for continued standard systemic anti-tumor therapy (chemotherapy, radiotherapy, immunotherapy, or targeted therapy), or for whom there are currently no proven effective and available targeted drugs; 6) Voluntary participation and signing of informed consent.
Exclusion criteria
Exclusion criteria: 1)Patients who have received any radiotherapy, chemotherapy, targeted therapy, or immunotherapy for tumors within the past month; 2) Patients with severe pulmonary fibrosis, especially drug-induced pulmonary fibrosis; 3) Patients with severe bleeding tendency, platelet count less than 50 *10^9/L, and severe coagulation disorders; 4) Pregnant and lactating women, or those with severe liver, kidney, heart, lung, or brain dysfunction, or those with severe anemia, dehydration, and severe nutritional and metabolic disorders that cannot be corrected or improved in the short term; or patients with severe systemic infection and high fever (T > 38.5?); 5) Patients who are HIV antibody positive, or have other acquired or congenital immunodeficiency diseases; 6) Patients with a history of organ transplantation; 7) Patients who have participated in other clinical trials within the past three months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Traditional Chinese Medicine Symptom Rating Scale;Quality of Life (EORTC QLQ-C30/LC13, FACT-L scales); | — |
Secondary
| Measure | Time frame |
|---|---|
| Tumor Response;Progression-Free Survival (PFS); | — |
Countries
China
Contacts
Public ContactGao Lei
Dongfang Hospital,Beijing University of Chinese Medicine
Outcome results
None listed